172 related articles for article (PubMed ID: 38229976)
1. Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report.
Alshurafa A; Afshan Adil ; Yassin MA
Case Rep Oncol; 2024; 17(1):96-100. PubMed ID: 38229976
[TBL] [Abstract][Full Text] [Related]
2. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
[TBL] [Abstract][Full Text] [Related]
3. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
[TBL] [Abstract][Full Text] [Related]
4. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.
Choi EJ
Blood Res; 2023 Apr; 58(S1):S29-S36. PubMed ID: 36891575
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
[TBL] [Abstract][Full Text] [Related]
6. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
García-Gutiérrez V; Hernandez-Boluda JC
Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
[TBL] [Abstract][Full Text] [Related]
8. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
Monestime S; Al Sagheer T; Tadros M
Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
[TBL] [Abstract][Full Text] [Related]
9. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D; Hughes TP
Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
[TBL] [Abstract][Full Text] [Related]
10. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
Minami Y; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Dawson MK; Matsumura I
Int J Hematol; 2024 Jun; ():. PubMed ID: 38888812
[TBL] [Abstract][Full Text] [Related]
11. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
Garcia Molina A
Farm Hosp; 2024 Apr; ():. PubMed ID: 38679535
[TBL] [Abstract][Full Text] [Related]
12. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP;
N Engl J Med; 2024 May; ():. PubMed ID: 38820078
[TBL] [Abstract][Full Text] [Related]
13. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A; Réa D; Boquimpani C; Minami Y; Cortes JE; Hughes TP; Apperley JF; Lomaia E; Voloshin S; Turkina A; Kim DW; Abdo A; Fogliatto LM; le Coutre P; Sasaki K; Kim DDH; Saussele S; Annunziata M; Chaudhri N; Chee L; García-Gutiérrez V; Kapoor S; Allepuz A; Quenet S; Bédoucha V; Mauro MJ
Leukemia; 2023 Mar; 37(3):617-626. PubMed ID: 36717654
[TBL] [Abstract][Full Text] [Related]
14. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Manley PW; Barys L; Cowan-Jacob SW
Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
[TBL] [Abstract][Full Text] [Related]
15. Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Hijiya N; Mauro MJ
Cancer Manag Res; 2023; 15():873-891. PubMed ID: 37641687
[TBL] [Abstract][Full Text] [Related]
16. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A; Pérez-Lamas L; Boque C; Giraldo P; Xicoy B; Ruiz Nuño C; Vega MM; Alvarez-Larrán A; Salamanca A; García-Noblejas A; Vall-Llovera F; Villalon L; De Las Heras N; Ramila E; Pérez-Encinas M; Cuevas B; Perez-Lopez R; Sanchez-Guijo F; Jiménez-Velasco A; Lakhwani S; Casado LF; Rosell A; Escola A; Fernández MJ; Garcia-Hernandez C; Cervero C; Mora E; Sagüés M; Suarez-Varela S; Vélez P; Carrascosa Mastell P; Bitaube RF; Serrano L; Cortes M; Vera Goñi JA; Steegmann JL; de Soria VGG; Alonso-Dominguez JM; Araujo MC; Coll AP; Hernandez-Boluda JC; García-Gutiérrez V
Ann Hematol; 2022 Oct; 101(10):2263-2270. PubMed ID: 35997804
[TBL] [Abstract][Full Text] [Related]
17. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
Atallah E; Mauro MJ; Hochhaus A; Boquimpani C; Minami Y; Maheshwari VK; Saini L; Corbin R; Réa D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6247-6262. PubMed ID: 36707445
[TBL] [Abstract][Full Text] [Related]
18. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
Tesileanu CMS; Michaleas S; Gonzalo Ruiz R; Mariz S; Fabriek BO; van Hennik PB; Dedorath J; Dekic B; Unkrig C; Brandt A; Koenig J; Enzmann H; Delgado J; Pignatti F
Oncologist; 2023 Jul; 28(7):628-632. PubMed ID: 37141403
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
Chee L; Lee N; Grigg A; Chen M; Schwarer A; Szer J; Ratnasingam S; Raj S; Lukito P; Yeung D; Hughes T; Shanmuganathan N
Intern Med J; 2024 Jun; ():. PubMed ID: 38884158
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Pérez-Lamas L; Luna A; Boque C; Xicoy B; Giraldo P; Pérez López R; Ruiz Nuño C; De Las Heras N; Mora Casterá E; López Marín J; Segura Díaz A; Gómez V; Vélez Tenza P; Sierra Pacho M; Vera Goñi JA; Moreno Vega M; Alvarez-Larrán A; Cortés M; Pérez Encinas M; Carrascosa Mastell P; Angona A; Rosell A; Lakhwani S; Colorado M; Ramila E; Cervero C; Cuevas B; Villalón Blanco L; de Paz R; Paz Coll A; Fernández MJ; Felipe Casado L; Alonso-Domínguez JM; Anguita Arance MM; Salamanca Cuenca A; Jiménez-Velasco A; Prendes SO; Santaliestra M; Lis Chulvi MJ; Hernández-Boluda JC; García-Gutiérrez V
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]